Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(2.29)
# 2,492
Out of 4,944 analysts
490
Total ratings
39.51%
Success rate
-1.72%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Buy | $54 → $30 | $14.39 | +108.48% | 15 | Aug 12, 2025 | |
| EOLS Evolus | Maintains: Buy | $27 → $20 | $6.51 | +207.22% | 28 | Aug 6, 2025 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $31 | $15.62 | +98.46% | 1 | Aug 6, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $105 → $115 | $49.05 | +134.45% | 25 | Aug 5, 2025 | |
| ARGX argenx SE | Maintains: Buy | $720 → $774 | $646.60 | +19.70% | 40 | Aug 1, 2025 | |
| ALKS Alkermes | Reiterates: Neutral | $46 | $28.63 | +60.67% | 24 | Jul 21, 2025 | |
| IRON Disc Medicine | Reiterates: Buy | $118 | $61.10 | +93.13% | 16 | Jul 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Buy | $81 | $30.09 | +169.19% | 24 | Jun 27, 2025 | |
| ROIV Roivant Sciences | Reiterates: Buy | $18 | $11.96 | +50.50% | 20 | Jun 18, 2025 | |
| CABA Cabaletta Bio | Reiterates: Buy | $25 | $1.71 | +1,361.99% | 26 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $56.72 | +41.04% | 33 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $37.67 | +40.70% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.00 | +600.70% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $6.47 | +116.38% | 17 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $18.86 | +80.32% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $15.63 | +21.56% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.11 | +468.72% | 17 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $4.78 | +276.57% | 14 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 | $15.89 | +220.96% | 22 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.56 | +1,057.56% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $57 | $26.58 | +114.45% | 26 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $12.42 | +20.77% | 15 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.81 | +176.24% | 14 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $3 | $2.13 | +40.85% | 16 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.84 | +108.33% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.80 | +44,900.00% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.14 | +777.19% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $176.29 | +3.24% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.25 | +158.62% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $30.96 | -41.86% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $17.21 | -53.52% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $24.96 | +108.38% | 2 | Jun 11, 2019 |
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $54 → $30
Current: $14.39
Upside: +108.48%
Evolus
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $6.51
Upside: +207.22%
Rapport Therapeutics
Aug 6, 2025
Initiates: Buy
Price Target: $31
Current: $15.62
Upside: +98.46%
Praxis Precision Medicines
Aug 5, 2025
Maintains: Buy
Price Target: $105 → $115
Current: $49.05
Upside: +134.45%
argenx SE
Aug 1, 2025
Maintains: Buy
Price Target: $720 → $774
Current: $646.60
Upside: +19.70%
Alkermes
Jul 21, 2025
Reiterates: Neutral
Price Target: $46
Current: $28.63
Upside: +60.67%
Disc Medicine
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $61.10
Upside: +93.13%
Crinetics Pharmaceuticals
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $30.09
Upside: +169.19%
Roivant Sciences
Jun 18, 2025
Reiterates: Buy
Price Target: $18
Current: $11.96
Upside: +50.50%
Cabaletta Bio
Jun 11, 2025
Reiterates: Buy
Price Target: $25
Current: $1.71
Upside: +1,361.99%
Jun 3, 2025
Reiterates: Buy
Price Target: $80
Current: $56.72
Upside: +41.04%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $37.67
Upside: +40.70%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.00
Upside: +600.70%
Apr 28, 2025
Reiterates: Buy
Price Target: $14
Current: $6.47
Upside: +116.38%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $18.86
Upside: +80.32%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $15.63
Upside: +21.56%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $2.11
Upside: +468.72%
Mar 20, 2025
Reiterates: Buy
Price Target: $18
Current: $4.78
Upside: +276.57%
Mar 19, 2025
Reiterates: Buy
Price Target: $51
Current: $15.89
Upside: +220.96%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.56
Upside: +1,057.56%
Mar 3, 2025
Reiterates: Buy
Price Target: $57
Current: $26.58
Upside: +114.45%
Feb 27, 2025
Reiterates: Buy
Price Target: $15
Current: $12.42
Upside: +20.77%
Feb 26, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.81
Upside: +176.24%
Feb 18, 2025
Maintains: Buy
Price Target: $30 → $3
Current: $2.13
Upside: +40.85%
Nov 7, 2024
Reiterates: Buy
Price Target: $8
Current: $3.84
Upside: +108.33%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.80
Upside: +44,900.00%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.14
Upside: +777.19%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $176.29
Upside: +3.24%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.25
Upside: +158.62%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $30.96
Upside: -41.86%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $17.21
Upside: -53.52%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $24.96
Upside: +108.38%